Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Performance Update

17 Nov 2015 14:30

RNS Number : 0291G
BlueCrest AllBlue Fund Ltd
17 November 2015
 



FOR IMMEDIATE RELEASE

 

17 November 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - OCTOBER 2015

 

"BlueCrest AllBlue delivered continued solid performance"

 

BlueCrest AllBlue Fund Limited (BCAB) delivered continued solid performance of 0.4% in October, bringing the gain for the year to date to 3.2% (Sterling Class NAV). The rolling 12 month return rose to 4.6% and volatility, at 3.1%, remained stable around historic norms.

 

Investor sentiment improved notably as October progressed and by month end, equity markets had produced strong gains, credit spreads had tightened and commodities had stabilised. However, markets seemed driven more by better sentiment than hard data as economic data were generally mixed and there were no changes to central bank policy, although the ECB hinted at an expansion of quantitative easing.

 

"Three of the seven strategies were positive"

 

Three of the seven strategies were positive in October, with the strongest performance coming from BlueCrest Quantitative Equity, up 1.8% for the month. BlueCrest Emerging Markets, BlueCrest Mercantile and BlueCrest Equity Strategies all posted small losses.

 

In October, BlueCrest Quantitative Equity produced strong returns as gains were seen across all regions, although Europe accounted for the majority of performance. Proprietary signals outperformed, with the European alpha capture signal being a strong contributor. As usual, net exposure remained tightly controlled around zero both overall and at a regional level.

BlueCrest Capital International also had another good month as opportunities in the fixed interest markets remain fruitful. Gains were derived principally from European trading and in cross market strategies, as divergent regional monetary policies continue to offer good trading opportunities. European trading benefitted from a long bias to European rates, positioning in dollar/euro and also from European curve steepeners. In North America, US relative value trading and Canadian curve flattening trades were also profitable, although mortgage trading detracted.

 

The principle detractor was BlueTrend 2x which fell by 3.8% in the month. Clearly the magnitude of BlueTrend 2x's performance is much larger than the prior unleveraged allocation, with the position size halved accordingly. Therefore, the impact at the AllBlue level is not magnified. BlueTrend saw six of its seven strategies produce negative returns with only the net short position in energy being positive. The model had to contend with sharp reversals early in the month and in some strategies such as equities, switched orientation accordingly. VaR levels finished October down slightly, although exposure to agriculture and energy increased.

 

No changes were made to allocations between the seven funds for November.

 

"It is likely that a continuation vote will be triggered"

 

The Company's discount remained stable during the month at a little over 5%, with the Company buying shares periodically. That said, the Company has outperformed its listed peer group, which are generally trading on wider discounts. It is likely that a continuation vote will be triggered in the near term in the Sterling shares and the Board will communicate with shareholders in the event that this occurs.

 

In January 2015, BlueCrest spun out the management of part of its systematic business into Systematica Investments, in which BlueCrest retained a stake. BlueCrest recently disposed of the majority of that holding; this does not impact the ability of AllBlue to invest into BlueTrend nor the AllBlue committee's access to information necessary to make its allocation decisions.

 

 

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRMMMMMDNVGKZM
Date   Source Headline
13th Oct 20175:52 pmRNSTransaction in Own Shares
10th Oct 201710:34 amRNSNet Asset Value(s)
6th Oct 20175:19 pmRNSTransaction in Own Shares
5th Oct 20172:55 pmRNSHolding(s) in Company
4th Oct 201710:39 amRNSNet Asset Value(s)
3rd Oct 20176:07 pmRNSHolding(s) in Company
26th Sep 201712:19 pmRNSSuccession Planning Update
26th Sep 201711:06 amRNSDirector's Other Directorship
26th Sep 201710:33 amRNSNet Asset Value(s)
22nd Sep 20175:23 pmRNSTransaction in Own Shares
22nd Sep 20173:44 pmRNSHalf-year Report
19th Sep 201710:38 amRNSNet Asset Value(s)
15th Sep 20175:31 pmRNSTransaction in Own Shares
12th Sep 201710:22 amRNSNet Asset Value(s)
6th Sep 20174:21 pmRNSHolding(s) in Company
6th Sep 20174:18 pmRNSHolding(s) in Company
6th Sep 201710:24 amRNSNet Asset Value(s)
5th Sep 20173:17 pmRNSHolding(s) in Company
31st Aug 20175:22 pmRNSEstimated Creditor Interests
29th Aug 201712:51 pmRNSNet Asset Value(s)
25th Aug 201712:59 pmRNSEstimated Creditors Interest
25th Aug 201712:57 pmRNSNet Asset Value(s)
22nd Aug 201711:11 amRNSNet Asset Value(s)
21st Aug 201710:26 amRNSDirector's Other Directorship
15th Aug 201711:23 amRNSNet Asset Value(s)
11th Aug 20175:07 pmRNSTransaction in Own Shares
8th Aug 201710:14 amRNSNet Asset Value(s)
3rd Aug 20172:25 pmRNSNet Asset Value(s)
31st Jul 20175:07 pmRNSInvestor Communication from AllBlue Limited
28th Jul 20173:37 pmRNSEstimated Creditor Interests
28th Jul 20173:30 pmRNSNet Asset Value(s)
25th Jul 201711:07 amRNSNet Asset Value(s)
19th Jul 20172:59 pmRNSResult of AGM
18th Jul 201712:53 pmRNSNet Asset Value(s)
11th Jul 20171:13 pmRNSNet Asset Value(s)
7th Jul 20179:57 amRNSConfirmation of AllBlue Proceeds Received
6th Jul 201710:14 amRNSNet Asset Value(s)
27th Jun 20179:33 amRNSNet Asset Value(s)
23rd Jun 20175:27 pmRNSTransaction in Own Shares
22nd Jun 201712:11 pmRNSEstimated Creditor Interests
22nd Jun 201712:10 pmRNSNet Asset Value(s)
20th Jun 201712:29 pmRNSNet Asset Value(s)
16th Jun 20175:17 pmRNSTransaction in Own Shares
16th Jun 201712:03 pmRNSHolding(s) in Company
14th Jun 201712:07 pmRNSHolding(s) in Company
13th Jun 201712:20 pmRNSNet Asset Value(s)
8th Jun 20174:26 pmRNSHolding(s) in Company
7th Jun 201711:39 amRNSNet Asset Value(s)
6th Jun 201711:51 amRNSNet Asset Value(s)
6th Jun 201711:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.